From: Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
Months 0-3
Months 0-6
Months 6-12
Annual Risk After 12 Months
Donepezil
5.1%
10.2%
10.3%
Memantine
3.1%
6.3%